Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00218075|
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : January 5, 2016
|Condition or disease||Intervention/treatment||Phase|
|Cocaine Abuse Cocaine-Related Disorders||Drug: Levodopa Drug: Carbidopa Behavioral: Clinical Management Behavioral: Relapse Prevention Therapy Behavioral: Contingency Management||Phase 2|
Cocaine is a strong central nervous system stimulant that is widely abused throughout the United States. Due to its widespread use, it is important to develop an effective treatment for cocaine dependence. Levodopa is a medication that is used alone or in combination with carbidopa to treat Parkinson's disease. The purpose of this study is to determine the possible interactions between behavioral interventions and carbidopa/levodopa in order to treat cocaine dependent individuals.
This study will last 12 weeks and will involve two phases. The first phase will include three therapy conditions: 1) clinical management only, 2) clinical management and relapse prevention therapy, and 3) clinical management, relapse prevention therapy, and contingency management. All of the conditions in the first phase will be evaluated incrementally under active and placebo conditions while participants receive carbidopa/levodopa.
The second phase of the study will examine the contingency management procedure applications. Each of the three contingency management procedure applications targets specific behaviors that, when reinforced, may interact with carbidopa/levodopa to produce clinical benefits. Participants will receive relapse prevention therapy combined with a contingency management procedure that targets clinic attendance, medication compliance, and cocaine abstinence. Study visits will occur weekly throughout the study. In addition, participants will complete a one-year follow-up visit.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Behavioral Strategies to Maximize the Efficacy of Pharmacotherapy for Cocaine Dependence: Relapse Prevention With Contingency Management Procedures|
|Study Start Date :||March 2000|
|Actual Primary Completion Date :||October 2007|
|Actual Study Completion Date :||October 2007|
- Cocaine use
- Medication compliance
- treatment retention
- severity of addiction-related problems
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00218075
|United States, Texas|
|University of Texas Health Science Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||John Grabowski, PhD||University of Texas|